4DFF

The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia

4DFF の概要

• エントリーDOI: 10.2210/pdb4dff/pdb
• 分子名称: cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, MAGNESIUM ION, ZINC ION, ... (5 entities in total)
• 機能のキーワード: zn binding, mg binding, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Cytoplasm: Q9Y233
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 81487.75

構造登録者

Ho, G.D.,Seganish, W.M.,Bercovici, A.,Tulshian, D.,Greenlee, W.J.,Van Rijn, R.,Hruza, A.,Xiao, L.,Rindgen, D.,Mullins, D.,Guzzi, M.,Zhang, X.,Bleichardt, C.,Hodgson, R. (登録日: 2012-01-23, 公開日: 2012-03-14, 最終更新日: 2012-04-04)

• 主引用文献: Ho, G.D.,Michael Seganish, W.,Bercovici, A.,Tulshian, D.,Greenlee, W.J.,Van Rijn, R.,Hruza, A.,Xiao, L.,Rindgen, D.,Mullins, D.,Guzzi, M.,Zhang, X.,Bleickardt, C.,Hodgson, R.; The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.; Bioorg.Med.Chem.Lett., 22:2585-2589, 2012; PubMed: 22377514; DOI: 10.1016/j.bmcl.2012.01.113

実験手法

X-RAY DIFFRACTION (2.11 Å)